PATENT Case No. 21126YP

Graser, Jennifer E.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit:

Examiner:

1645

Hamelin, et al.

Serial No.

10/521,300

Filed:

January 14, 2005

For: METHOD FOR IDENTIFYING CELLULAR GROWTH

INHIBITORS

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I HEREBY CERTIFY THAT THIS CORRE **ERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRES**

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

| | RELATED APPLICATION | | | | | |
|--|---|---|--|--|--|--|
| U. S. SERIAL NUMBER | FILING DATE | MERCK CASE | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| If this is inconvenient, additional copies will be submitted u | pon request. | | | | | |
| 6. In accordance with 37 C.F.R. 1.97, (check one) | | | | | | |
| the attached information is filed within three months of | the filing date of the captioned case. | | | | | |
| the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits. | | | | | | |
| the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114. | | | | | | |
| the attached information is being filed more than three Office Action on the merits, but before the mailing date otherwise closes prosecution in the application. The exaccount No. 13-2755 for the fee required under 37 C.F. | of a Final Action, Notice of Allowand nclosed authorization is therefore giv | ce, or an action that | | | | |
| each item of information contained in this Information I from a foreign patent office in a counterpart foreign appointment. | Disclosure Statement was first cited i plication not more than three months | n any communication prior to the filing of this | | | | |
| each item of information contained in the information of a foreign patent office in a counterpart application and designated in §1.56(c) more than thirty days prior to the | this communication was not receive | d by any individual | | | | |
| no item of information contained in this Information Disforeign patent office in a counterpart foreign application after making reasonable inquiry, was known to any ind months prior to the filing of this Statement. | n, and, to the knowledge of the perso | on signing the certification | | | | |
| A copy of the EPO search report is also enclosed. | Respectfully submitted, Funding R. Wasser By: Kenneth R. Walton | tto | | | | |
| | Attorney For A | pplicant(s) | | | | |
| | Reg. No. 32,951 MERCK & CO., INC. Patent Dept., RY60-30 | | | | | |
| | P.O. Box 2000 Rahway, N.J. 07065-09 (732)594- <u>3462</u> | 907 — | | | | |

Date: September 13, 2006

| | | | | | Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE | |
|---------------------------|--|------|------------|------------------------------|---|--|
| | Substitute for form 1449B/PTO | | | COMPLETE IF KNOWN | | |
| INFORMATION DISCLOSURE | | | SCLOSURE | Application Number | 10/521,300 | |
| IP STATEMENT BY APPLICANT | | | | Filing Date | January 14, 2005 | |
| / | | | | First Named Inventor | Michel J. Hamelin | |
| , | EP 13 2006 (user as many sheets | as 1 | necessarv) | Group Art Unit | 1645 | |
| 1.4 | | | | Examiner Name | Graser, Jennifer E. | |
| <u> </u> | 2 Shere 1 | of | 1 | Attorney Docket Number | 21126YP | |
| 1.4 | The state of the s | | | Group Art Unit Examiner Name | 1645 Graser, Jennifer E. | |

| NON PATENT LITERATURE DOCUMENTS Examiner Cite | | | | | | | | |
|--|---|--|--|--|--|--|--|--|
| No. | E Total de Control de | | | | | | | |
| 1 | Kinzel, B., et al., "Downregulation of Hus1 by Antisense Oligonucleotides Enhances the Sensitivity of Human Lung Carcinoma Cells to Cisplatin", Cancer, Vol. 94, No. 6, pp. 1808-1814 (2002) | | | | | | | |
| 2 | Hartwell, L. H., et al., "Integrating Genetic Approaches into the Discovery of Anticancer Drugs", Science, Vol. 278, pp. 1064-1068 (1997) | | | | | | | |
| 3 | Measday, V., et al., "Synthetic Dosage Lethality", Methods in Enzymology, Vol. 350, pp. 316-326 (2002) | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | 2 | | | | | | | |

| Evernine | | | | | |
|------------|--|------------|---|--|--|
| Examiner | | Data | | | |
| Signature | | Date | 1 | | |
| o ignature | | Considered | 1 | | |
| | | Considered | | | |

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.